Navigation Links
INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Date:10/13/2007

, talk to your healthcare professional.

Inform your healthcare professional if you are pregnant or if you are planning to get pregnant while taking INVEGA. Do not breast-feed if you are taking INVEGA.

INVEGA may affect your driving ability; therefore, do not drive or operate machines before talking to your healthcare professional. Avoid alcohol while on INVEGA.

INVEGA may affect alertness and motor skills; use caution until the effect of INVEGA is known.

INVEGA may make you more sensitive to heat. You may have trouble cooling off, or be more likely to become dehydrated, so take care when exercising or when doing things that make you warm.

INVEGA should be swallowed whole. Tablets should not be chewed, divided, or crushed. Do not be worried if you see something that looks like a tablet in your stool. This is what is left of the tablet after all the medicine has been released.

Janssen, L.P., based in Titusville, N.J., is the only pharmaceutical company in the U.S. dedicated solely to mental health. The company currently markets prescription medications for the treatment of schizophrenia, bipolar mania, and irritability associated with autistic disorder.

For more information about Janssen, L.P., visit http://www.janssen.com.

(a) Quetiapine, commercially available as SEROQUEL(R), was approved for the treatment of schizophrenia in 1997 and is one of the most prescribed atypical antipsychotic agents of the dibenzothiazepine class (all atypical prescriptions, total prescriptions Jan 05 - April 07; new prescriptions Sept 04 - April 07, IMS Health, National Prescription Audit).

(b) Positive and Negative Syndrome Scale for Schizophrenia (PANSS) is a standard rating scale used in trials to assess the severity of symptoms. The scale consists of 30 items, which are assessed from absent to extreme, and these are divided into both positive and negative symptoms.

Reference
'/>"/>

SOURCE Janssen, L.P. and Johnson & Johnson
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
2. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
3. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
6. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
7. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
8. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
9. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
10. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
11. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014  Sutro Biopharma today announced that ... one of 2014,s Fierce 15 biotechnology companies, designating it ... in the industry.  "Sutro has earned ... as well as industry partners for what promises to ... bispecifics," says John Carroll , editor of ...
(Date:9/22/2014)... YORK , Sept. 22, 2014 ... exclusive, global license agreement with Plasma Technologies LLC ... proprietary plasma fractionation process. Concurrently, the Company announced ... to strategically refocus and rebrand the company as ... a national listing for its common shares. ...
(Date:9/22/2014)... Research and Markets  has announced the addition of ... report to their offering. The ... professional and in-depth study on the current state of ... Chinese situation. The report provides a basic ... industry chain structure. The diclofenac market analysis is provided ...
Breaking Medicine Technology:FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Global and Chinese Diclofenac Industry Report 2014 2
... 24, 2011 Thomas Huxtable and his wife, Danielle, filed ... Inc. seeking compensation for injuries caused by the failure of ... has been recalled.  John David Hart of the Law Offices ... attorney representing Mr. and Mrs. Huxtable in the lawsuit filed ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), ... human disease, announced today that Pablo Lapuerta, M.D. has ... for directing clinical development of Lexicon,s drug candidates from ... Lapuerta has 15 years of pharmaceutical industry experience in ...
Cached Medicine Technology:DePuy Recalled Hip Device Lawsuit Filed in Austin, Texas 2Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer 2Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer 3
(Date:9/22/2014)... 22, 2014 Quincy Bioscience, one ... States, promotes National Self-Improvement Month this ... individuals should have access to self-improvement resources, especially ... The demand for products that preserve health is ... before. For over six years, Quincy Bioscience has ...
(Date:9/22/2014)... Scans of young children,s brains might help predict ... potentially allow doctors to identify those with dyslexia ... suggests. "Early identification and interventions are extremely ... most neurodevelopmental disorders," the study,s senior author, Dr. ... adolescent psychiatry at University of California, San Francisco ...
(Date:9/22/2014)... In a continued effort to support the ... launching an awareness campaign inspired by the ice bucket ... to raise awareness and funds for the cause. , ... the air and trying to catch it while blindfolded. ... nominee does not complete the challenge within 24 hours ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 The struggles ... English proficiency (LEP) patients has been well-documented—reportedly, language barriers ... repeat visits to the emergency room and an increased ... , At Sanford Health, the largest medical facility ... a rising LEP population necessitated the need for ...
(Date:9/22/2014)... Tenn. (PRWEB) September 22, 2014 ... contact center and customer service solutions. , WHAT: ... is focused on customer care for the connected ... landscapes continue to offer new challenges and opportunities ... to helping attendees identify best practices, network and ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 3Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... is associated with an increased risk of heart failure and ... concludes a study published on bmj.com today. ... continued use of rosiglitazone for most patients. Rosiglitazone and ... are widely used for the treatment of type 2 diabetes. ...
... year, 500,000 project to co-ordinate European and international ... treat malaria. The CRIMALDDI project (Coordination, Rationalisation ... Initiatives) is being led by the Liverpool School ... players in the antimalarial drug discovery fields including ...
... Having 45 million doses by Oct. 15 will still be ... Health experts do not believe that the delay in receiving ... protect Americans against the newly circulating virus. , But having ... than the originally anticipated 120 million doses, does throw a ...
... , MONROVIA, Calif., Aug. 20 STAAR Surgical Company ... minimally invasive ophthalmic products, today reported on the status of its application ... , , As anticipated, the Ministry of Health, Labour ... in Japan, at which time the STAAR Visian ICL products were considered ...
... ... and innovative charitable program that provides free hair restoration services to children suffering from ... ... , the world,s first online social network community dedicated to all-things hair loss has ...
... ... Sparsense, the developer of a novel image and signal processing ... firm. The exclusive partnership will allow the development of various custom ... applications. The new technology can be applied to MRI, MR video ...
Cached Medicine News:Health News:Diabetes drug linked to increased risk of heart failure 2Health News:LSTM to lead EU project to coordinate antimalarial drug research 2Health News:Swine Flu Vaccine Delay Manageable, Experts Say 2Health News:Swine Flu Vaccine Delay Manageable, Experts Say 3Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 2Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 3Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 4Health News:Hair Loss Website Launches Program for Children 2Health News:Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 2Health News:Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: